Thanks for the link to the detailed report! Just skimmed it right now but seems really detailed on the compounds
Dinaciclib is a compound I have not looked into. Any idea on the royalty? I just skimmed the report so perhaps its in there.
I agree on Promacta when I bought the stock I thought they could get to 400-500M assuming they get approved in some oncology indications. Ligand would do quite nicely (for their size) at that (~25-35 million). I thought we would (perhaps still) get a pickup in sales with the removal of the REMS (it was December '11).
I am still hopeful our Carfilzomib royalty is 2%+ and not just 1% which could be a nice amount (especially considering what they paid for CyDex.
So far their deals have been pretty good (what I like to call as Ben Graham type deals). Nothing spectacular but paying peanuts for the assets. I think as their revenue base grows they could start to acquire more meaningful royalties/potential royalties.
I think the at-the-market offering wasn't the best way to raise funds and is a bit of an overhang. Owning royalty companies in the past I know they need to raise money and am OK with that (as long as its done opportunistically) just the way they did it wasn't the best IMO.
Market Data 
Markets 
AI
